JPJennifer M. Puck

Jennifer M. Puck

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jennifer M. Puck has a total of 595 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Host genomics in diagnosing inborn errors of immunity and tailoring infectious disease treatments

    by Lucas Buyon, Jonathan S. Berg, Dusan Bogunovic, Eric D. Green, Steven M. Holland, Jahnavi Narula, Sarah W. Read, Alauna Rupert, Jeanne M. Marrazzo, Jennifer M. Puck

    Genomic technologies are widely applied clinically to identify pathogens and their antimicrobial susceptibilities, but less use is made of patients’ germline genomic variations in infectious disease management. Not only can inborn errors of immunity (IEIs), most of which are rare, be detected before severe complications develop, but host genomics can assist with risk stratification for severe common infections, antimicrobial therapy selection, and pharmacogenomic-guided dosing. Over 30 clinical immunologists, infectious disease specialists and geneticists met to outline challenges and opportunities concerning host genomics and infectious diseases. Obstacles identified included payer requirements for extensive conventional diagnostics prior to genetic testing, lack of electronic health record (EHR) interoperability, and limited evidence of efficacy and cost-effectiveness given the individual rarity of most IEIs. Priorities to broaden the use of host genomics include publicizing indicators of IEIs, building them into EHR informatics systems, and promoting multidisciplinary approaches to identifying patients with IEIs.

  • Selection of Genetic Conditions for Multi-State Genomic Newborn Screening in BRIDGES-NBS

    by Nina B. Gold, Britt A. Johnson, Harini Somanchi, Thomas Minten, Stephanie A. Coury, Carrie Blout Zawatsky, Amber Begtrup, Elizabeth Butler, Katherine G. Langley, Rebekah Zimmerman, et al.

  • Open Access

    Trajectory of Hyper IgE complications

    by Asteria Mao, Rui Xiao, Kathleen E Sullivan, Ramsay Fuleihan, Charlotte Cunningham-Rundles, Jennifer Puck, Rebecca Marsh, Roshini Abraham, Luigi Daniele Notarangelo, Vaibhavi Vichare, et al.

    Objective Our objective was to define the natural history of hyper IgE syndrome. Well, there have been a number of large cross-sectional studies. It has been difficult to provide anticipatory care for the growing adult population. Methods The USIDNET registry was used to identify patients with hyper IgE syndrome. We evaluated all patients regardless of genetic etiology. Complications were extracted as text from the problem list or ICD codes, and each complication was date stamped, which allowed us to estimate the age at which the complication arose. Results Many of the complications previously identified were seen in this cohort. The most feared complications were uncommon, however, developmental delay and psychosis affected nearly a fifth of the cohort which has not been previously reported. Conclusions As the number of adults with hyper IgE syndrome increases our awareness of late onset complications is important. Aspergillus and pneumatoceles were less common than seen in some other cohorts. However, the significant rate of psychosis will represent a significant challenge for clinicians.

  • Open Access

    Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report

    by Lena E. Winestone, Brent R. Logan, Xuerong Liu, Olatundun Williams, Elizabeth A. Dunn, Monica S. Thakar, Sharon A. Kidd, Talal Mousallem, Morna J. Dorsey, Richard J. O’REilly, et al.

    Winestone et al. demonstrate that in 796 children with SCID transplanted with nonsibling donors between 1982 and 2020, survival was 18.8% lower among Black patients, 14.4% lower among Asian/Pacific Islander patients, and 6.9% lower among Hispanic patients compared with non-Hispanic White patients (P < 0.01). Newborn screening for SCID mitigates wide disparities between Black and non-Hispanic White patients.


  • Open Access

    CRISPR-mediated functional mapping of IL2RG variants in primary human T cells predicts X-linked severe combined immunodeficiency

    by Yvonne Rong, Mikhail Vysotskiy, Peixin Amy Chen, Ekansh Agrawal, Edward Marsh, Charlotte H. Wang, Daniel Carr, Rama Dajani, Brenna Gittins Maker, Furong Yu, et al.

    Distinguishing pathogenic from benign mutation is critical for genetic diagnosis. A CRISPR-targeted saturation genome editing (SGE) platform in primary human cells assessed 489 single nucleotide variants (SNVs) in exon 5 of IL2RG, the gene causing X-linked SCID. The functional impact was clearly defined for 470 variants, agreeing with 100% (18/18) of ClinVar-deposited benign or likely benign annotations, and 100% (42/42) of pathogenic or likely pathogenic annotations. We discovered 90 novel loss-of-function mutations and validated an expected block in T-lymphocyte differentiation from edited hematopoietic stem cells.

  • Open Access

    Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report

    by Jessie L. Alexander, Blachy J. Dávila Saldaña, Ruta Brazauskas, Sravya Gethika Dammalapati, Linda M. Griffith, Ami J. Shah, Kristin A. Shimano, Hans D. Ochs, Jack J. Bleesing, Christen L. Ebens, et al.

    Wiskott-Aldrich syndrome (WAS), an X-linked disorder characterized by immunodeficiency, thrombocytopenia, autoimmunity, and malignancy, can be effectively treated with allogeneic hematopoietic cell transplantation (HCT). Older age at HCT and mismatched donors are known to affect overall survival (OS). However, the influence of specific clinical manifestations or WAS variant class on OS and factors associated with event-free survival (EFS) remain incompletely defined. We analyzed outcomes of 308 patients with WAS who underwent HCT at 37 institutions of the Primary Immune Deficiency Treatment Consortium from 1990 to 2018. With a median follow-up of 5.3 years, the 5-year OS and EFS were 87.2% and 79.7%, respectively. Age ≥5 years, donor type, and a pre-HCT history of severe infection had a negative impact on OS and EFS, whereas pre-HCT autoimmunity had no impact. Reduced-intensity regimens were associated with lower T-cell and myeloid donor chimerism, particularly when non–busulfan-based regimens were used. Low myeloid donor chimerism was associated with lower platelet counts. Mixed chimerism was not consistently associated with post-HCT autoimmunity. Patients with class I (exon 1-2 missense and intron 5 hot spot variants) and class II variants (all others) had similar pre-HCT clinical symptom severity and no difference in OS, EFS, or platelet recovery post-HCT. In conclusion, our study showed excellent long-term OS and EFS after HCT for WAS, highlighting the importance of early HCT, before the development of severe infections. We confirmed that HCT using busulfan-based conditioning was associated with improved donor chimerism and platelet recovery. This trial was registered at www.clinicaltrials.gov as NCT02064933.


  • Open Access

    Outcomes following matched sibling donor transplantation for severe combined immunodeficiency: a report from the PIDTC

    by Ahmad Rayes, Brent R. Logan, Xuerong Liu, Jasmeen Dara, Rebecca H. Buckley, Joseph H. Oved, Neena Kapoor, Malika Kapadia, Sharat Chandra, Caridad A. Martinez, et al.

    The Primary Immune Deficiency Treatment Consortium performed a retrospective analysis of 133 patients with severe combined immunodeficiency (SCID) receiving matched sibling donor (MSD) hematopoietic cell transplantation (HCT) between 1980 and 2023 at 30 North American institutions. In this largest cohort of MSD outcomes in patients with SCID to date, we examined the impact of conditioning regimen and graft-versus-host disease (GVHD) prophylaxis on survival and immune recovery. Outcomes after MSD HCT for SCID were excellent. Patients without an active infection or failure to thrive (FTT) at the time of HCT had 5-year overall survival superior to those with infection or FTT. Acute and chronic GVHD outcomes were independent of GVHD prophylaxis, conditioning regimen, SCID type, or presence of maternal engraftment. Patients without active infection at the time of HCT had superior chronic GVHD-free event-free survival vs those with infection. T-cell reconstitution at 6 months was less likely achieved with use of GVHD prophylaxis or serotherapy, and in patients with leaky SCID or Omenn syndrome. At 6 months, 1 year, and 2-5 years, T-cell reconstitution was less likely with ADA, DCLRE1C, or RAG genotype. B-cell reconstitution at 1 year and 2-5 years was negatively affected by development of grade 2 to 4 or 3 to 4 acute GVHD. Conditioning did not affect T- or B-cell reconstitution. Our data suggest omitting conditioning and GVHD prophylaxis for patients with typical SCID did not negatively affect 5-year outcomes after MSD HCT, but the data are insufficient to recommend this approach for best long-term outcomes. This trial was registered at www.clinicaltrials.gov as #NCT01186913 and #NCT01346150.


  • Open Access

    Neurodevelopmental outcomes following hematopoietic cell transplantation for patients with severe combined immunodeficiency (SCID): A PIDTC study

    by Virdette L. Brumm, Sharon A. Kidd, Brent R. Logan, Farheen Chunara, Jennifer Heimall, Linda M. Griffith, Donald B. Kohn, Lauren Sanchez, Jeffrey J. Bednarski, Caridad Martinez, et al.

    Hematopoietic cell transplantation (HCT) is a potentially curative treatment for severe combined immunodeficiency (SCID). Since the initiation of newborn screening (NBS), survival rates have improved significantly, but the impact of HCT upon neurodevelopment for patients with SCID requires more investigation. We performed a cross-sectional study of subjects with SCID in North America to assess the impact of NBS, transplant conditioning regimen, and genotype on neurodevelopmental outcomes after HCT. 69 subjects with SCID from 17 PIDTC centers (excluding those with ADA deficiency), ages 6–16 years, received comprehensive standardized neurodevelopmental testing of cognitive, behavioral, and emotional function. Compared with the normative population, our subjects performed in the average range. We found no impact of NBS, chemotherapy conditioning, or genotype. Multivariate analysis revealed a significant decrease in IQ in subjects whose families earned <$50,000 per year. We recommend that children treated by HCT for SCID be monitored with periodic cognitive and behavioral assessments for deficits that could potentially impact long-term ND outcomes.

  • Open Access

    Automated data extraction model for the USIDNET registry: Bigger, faster, and better data collection

    by Vaibhavi Vichare, Gonench Kilich, Charlotte Cunningham-Rundles, Michelle Onyekaba, Roshini S. Abraham, Jennifer Puck, Ramsay Fuleihan, Rebecca A. Marsh, Kathleen E. Sullivan

    The United States Immunodeficiency Network (USIDNET) is an NIH-funded research consortium that advances scientific investigation on inborn errors of immunity (IEIs). Formerly, USIDNET registry data were collected via an opt-in system with patient informed consent. The current registry uses semiautomated, de-identified data extraction from EPIC with a consent waiver. This study was performed to assess whether the new method improved enrollment using data from one site. Diagnoses, sex, and age within the new (n = 2,796) and old (n = 551) registries were defined. The new registry enrolled more subjects and had six times more clinical features recorded per patient on average and 22 times more laboratory data recorded per patient. Response to queries is much more rapid, with execution of a database query within a day. There were differences in enrollment demographics depending on underlying diagnosis. The design of the new USIDNET registry may better capture a greater number and representation of patients compared to the old registry.


  • Open Access

    The ClinGen Severe Combined Immunodeficiency Disease Variant Curation Expert Panel: Specifications for classification of variants in ADA, DCLRE1C, IL2RG, IL7R, JAK3, RAG1, and RAG2

    by Vanessa C. Jacovas, Michelle Zelnick, Shannon McNulty, Justyne E. Ross, Namrata Khurana, Xueyang Pan, Alejandro Nieto, Shiloh Martin, Benjamin McLean, Marwa A. Elnagheeb, et al.